Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases

BACKGROUND: Most patients with epidermal growth factor receptor mutation-positive (EGFRm) non-small-cell lung cancer (NSCLC) acquire resistance to first-line (1L) first- or second-generation (1G/2G) EGFR-TKIs; therefore, it is important to optimize 1L treatment to improve patient outcomes. OBJECTIVE...

Descripción completa

Detalles Bibliográficos
Autores principales: Soo, Ross A., Seto, Takashi, Gray, Jhanelle E., Thiel, Ellen, Taylor, Aliki, Sawyer, William, Karimi, Parisa, Marchlewicz, Elizabeth, Brouillette, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844326/
https://www.ncbi.nlm.nih.gov/pubmed/34510401
http://dx.doi.org/10.1007/s40801-021-00272-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844326/
https://www.ncbi.nlm.nih.gov/pubmed/34510401
http://dx.doi.org/10.1007/s40801-021-00272-5

Ejemplares similares